Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) AI Stock Analysis

• Market Cap: HK$6.47B
• Dividend Yield: 3.27%
• Average Volume (3M): 1.44M
• Price to Earnings (P/E): 31.2
• Beta (1Y): 1.17
• Revenue Growth: -32.05%
• EPS Growth: -54.47%
• Country: HK
• Employees: 1,237
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Devices
• EPS (TTM): 0.36
• Shares Outstanding: 95,140,500
• 10 Day Avg. Volume: 1,122,250
• 30 Day Avg. Volume: 1,439,996
• PEG Ratio: -1.26
• Price to Book (P/B): 1.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 335.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: HK$11.00 ▼(-1.79%Downside)

The stock's overall score of 65 reflects strong balance sheet stability and positive technical momentum. However, challenges in revenue generation and negative cash flows from operations present significant risks. The stock's valuation is reasonable, supported by a healthy dividend yield. Addressing the cash flow issues is crucial for future growth prospects.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) is a leading Chinese company specializing in the research, development, production, and sale of orthopedic implants and medical instruments. The company operates primarily in the healthcare sector, focusing on providing high-quality products such as joint prostheses and spinal implants to meet the growing demands of the medical industry both domestically and internationally.

How the Company Makes Money

Beijing Chunlizhengda Medical Instruments Co., Ltd. generates revenue through the manufacture and sale of orthopedic medical devices. The company's primary revenue streams include the sale of joint prostheses and spinal implant products. These products are distributed to hospitals and healthcare providers in China and other international markets. The company invests in research and development to innovate and enhance its product offerings, ensuring compliance with regulatory standards and catering to the evolving needs of the healthcare industry. Strategic partnerships with medical institutions and expansion into new markets also play a crucial role in driving its sales and overall financial performance.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H exhibits strong balance sheet stability with minimal debt levels. However, the decrease in revenue and profitability margins, coupled with negative cash flow from operations, indicate potential financial stress. The company needs to address revenue generation and improve operational cash flows to sustain long-term growth.

Income Statement

The gross profit margin remains strong at 64.08% in 2024, indicating efficient cost management in production. However, revenue showed a significant decline of 33.33% from 2023 to 2024, indicating challenges in maintaining sales volumes. The net profit margin also decreased, reflecting reduced profitability. EBIT and EBITDA margins have also decreased, suggesting pressures on operational efficiency.

Balance Sheet

The company maintains a solid equity position with a debt-to-equity ratio of 0.0003, indicating minimal leverage and financial risk. The equity ratio is robust at 81.38%, showcasing strong financial stability. Despite a slight drop in stockholders' equity, the company's balance sheet remains strong.

Cash Flow

The operating cash flow turned negative in 2024, indicating issues in cash generation from core operations. Free cash flow has also declined, pointing to challenges in maintaining liquidity. The free cash flow to net income ratio is negative, highlighting the need for cash management improvements.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
805.86M	1.21B	1.20B	1.11B	937.69M
	Gross Profit
516.49M	875.89M	913.53M	854.54M	680.76M
	EBIT
130.71M	305.98M	328.91M	367.59M	330.10M
	EBITDA
169.32M	340.65M	366.96M	360.99M	349.78M
	Net Income Common Stockholders
124.99M	277.82M	307.72M	322.36M	283.37M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.89B	2.10B	1.72B	1.74B	690.12M
	Total Assets
3.47B	3.65B	3.41B	3.00B	1.54B
	Total Debt
866.44K	1.75M	1.31M	1.23M	1.85M
	Net Debt
-1.14B	-1.26B	-955.88M	-1.74B	-688.26M
	Total Liabilities
644.39M	770.33M	690.07M	530.58M	460.41M
	Stockholders Equity
2.82B	2.88B	2.72B	2.47B	1.08B
Cash Flow		Free Cash Flow
-51.07M	478.47M	16.10M	-34.62M	236.68M
	Operating Cash Flow
-1.90M	511.71M	41.01M	164.79M	260.68M
	Investing Cash Flow
55.84M	-81.56M	―	―	―
	Financing Cash Flow
-183.14M	-121.33M	―	1.07B	-11.88M

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1858, the sentiment is Positive. The current price of 11.2 is above the 20-day moving average (MA) of 10.81, above the 50-day MA of 9.89, and above the 200-day MA of 8.64, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 65.18 is Neutral, neither overbought nor oversold. The STOCH value of 62.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1858.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1066	77 Outperform	$26.32B	11.79	8.95%	4.62%	-3.09%	0.67%
1513	74 Outperform	HK$35.91B	13.31	14.56%	4.50%	-5.37%	6.28%
1177	66 Neutral	$85.31B	44.96	6.14%	1.22%	7.63%	-24.23%
1858	65 Neutral	HK$6.47B	31.20	4.39%	3.27%	-32.05%	-54.47%
2196	65 Neutral	$69.10B	15.33	6.22%	1.96%	-2.82%	11.93%
1347	56 Neutral	HK$61.79B	261.00	0.42%	0.53%	-2.06%	-83.44%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Corporate Events

Beijing Chunlizhengda Announces H Shareholders’ Class Meeting for Share Repurchase Mandate

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a class meeting for H shareholders to discuss a special resolution regarding the repurchase of H Shares. The proposed mandate would allow the board to repurchase up to 10% of the total H Shares, excluding treasury shares, based on market conditions and company needs. This move could potentially impact the company’s share capital structure and market positioning, reflecting strategic financial management to enhance shareholder value.

Beijing Chunlizhengda Schedules 2024 AGM with Key Resolutions on Agenda

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, set for June 26, 2025. Key resolutions to be discussed include the approval of the 2024 profit distribution plan, remuneration for directors and supervisors for 2025, and the re-appointment of auditors. Additionally, a special resolution will consider granting the board a mandate to repurchase up to 10% of its H Shares, reflecting the company’s strategic financial management and commitment to shareholder value.

Beijing Chunlizhengda Announces Leadership Changes in Financial Management

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the resignation of two senior management members, Mr. Zhai Zhiyong and Ms. Li Yumei, due to personal reasons. Both will continue to serve the company in other capacities. The company appointed Ms. Lu Hongyue as the new Chief Financial Officer, effective immediately, to ensure continuity in financial management. This leadership change is expected to support the company’s ongoing financial strategies and operations.

Beijing Chunlizhengda Medical Instruments Reports Q1 2025 Financial Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. has released its unaudited financial results for the first quarter of 2025, in compliance with the Chinese Accounting Standards for Business Enterprises. The report, available in both Chinese and English, highlights the company’s financial performance for the three months ending March 31, 2025. Stakeholders are advised to consider potential investment risks as the data has not been audited.

Beijing Chunlizhengda Medical Instruments Announces Board Meeting for Quarterly Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced a board meeting scheduled for April 29, 2025, to approve the company’s first quarterly results for the period ending March 31, 2025, and to consider the payment of an interim dividend. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.

Beijing Chunlizhengda Medical Instruments Invests in Structured Deposit Products

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced its subscription to structured deposit products with China Construction Bank and Bank of Beijing, totaling RMB860 million. These transactions, funded by temporary idle proceeds and internal resources, are classified as discloseable transactions under Hong Kong’s listing rules, indicating a strategic move to optimize financial resources without requiring shareholder approval.

Beijing Chunlizhengda Announces 2024 Cash Dividend

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced a cash dividend of RMB 0.49 per 10 shares for the financial year ending December 31, 2024. This announcement reflects the company’s financial performance and commitment to delivering shareholder value, with the dividend subject to shareholder approval on June 26, 2025, and payment scheduled for July 31, 2025.

Beijing Chunlizhengda Medical Instruments Reports 2024 Financial Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced its audited consolidated results for the year ending December 31, 2024. The results, prepared according to the applicable disclosure provisions and accounting standards of China, reveal a decrease in total assets from the previous year, with notable changes in current and non-current assets, including an increase in inventories and a decrease in accounts receivable. These financial shifts could impact the company’s operational strategies and market positioning.

Beijing Chunlizhengda Medical Instruments Announces Upcoming Board Meeting

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a board meeting scheduled for March 28, 2025, to approve the annual results for the financial year ending December 31, 2024, and consider the payment of a final dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential returns on investment.